LianBio Gets Chinese Biotech US IPOs Rolling Again But Followers Scant
Health Players Turn Inward-Looking
Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.
You may also be interested in...
The torpedoed IPO application of a Shanghai-based biotech has already triggered a ripple of unease among venture capitalists in China, with some signaling suspension of investment in similar ventures.
Big data player and “Flatiron of China” is putting off its plans to go public amid regulatory scrutiny over DiDi and other companies listed in the US, but biotech firms need to worry less, says one investor.
From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.